{"id":816738,"date":"2025-02-24T10:35:59","date_gmt":"2025-02-24T15:35:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/"},"modified":"2025-02-24T10:35:59","modified_gmt":"2025-02-24T15:35:59","slug":"tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/","title":{"rendered":"Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team<\/b><\/p>\n<p class=\"bwalignc\">\nHandley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma<\/p>\n<p>FREMONT, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nTivic Health\u00ae Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies.<\/p>\n<p>\nHis key responsibilities will include building and leading Tivic\u2019s Biopharma team, advancing Tivic\u2019s recently licensed, late-stage product candidate,<strong \/>Entolimod\u2122,<strong \/>through manufacturing validation, regulatory approval processes and commercialization, and directing pipeline development activity.<\/p>\n<p>\n\u201cMike brings to Tivic a rare blend of device and pharmaceutical background, as well as proven operational, business and scientific experience that sets Tivic up for a smooth and successful expansion into drug development,\u201d stated Tivic Health Chief Executive Officer, Jennifer Ernst.<\/p>\n<p>\n\u201cWith our recent licensing of the late-stage TLR5 agonist, Entolimod, from Statera Biopharma, and Mike\u2019s deep experience in immunology and biotech, we believe that he is the ideal leader to establish Tivic\u2019s biopharmaceutical capabilities and advance our therapeutics pipeline. In tandem, we continue to pursue the development and exciting promise of our non-invasive bioelectronic vagus nerve stimulation, creating a portfolio of device and drug therapeutics from which to build shareholder value,\u201d added Ernst.<\/p>\n<p>\nOver the course of his career, Michael has successfully led or assisted in the global commercialization of 17 drugs and devices that represented ~$7 billion in annual sales. Additionally, he served as part of the management teams of successful exits to Johnson &amp; Johnson and Boston Scientific. He has successfully led teams in a variety of capacities in high growth organizations. As CEO, President and Chairman of the Board of Statera, Michael created and executed the company\u2019s growth strategy, advanced clinical development and intellectual property strategies, and spearheaded the company\u2019s business development and financing activities.<\/p>\n<p>\n\u201cThis is an exciting and critical time at Tivic Health, and I am thrilled to join the Tivic leadership team to continue the essential work of advancing Entolimod towards potential commercialization,\u201d stated Handley. \u201cWith compelling evidence of preventing death following a potential lethal dose of radiation and the opportunity to expand to adjacent indications in radiation toxicity and immune system dysregulation, I believe that Entolimod serves as a great foundation on which to build and potentially expand Tivic Health\u2019s biopharma pipeline.\u201d<\/p>\n<p><b>Inducement Grants under Nasdaq Listing Rule 5635(c)(4)<\/b><\/p>\n<p>\nIn connection with, and as a material inducement to, the hiring and appointment of Michael as Chief Operating Officer of Tivic Health and President of Tivic Biopharma, Tivic agreed to grant Michael 600,000 restricted stock units (RSUs), which shall vest over four years, with one fourth of the RSUs vesting on the one-year anniversary of the date of grant and the remaining RSUs vesting in 12 equal quarterly installments thereafter until fully vested. The vesting of shares of common stock underlying the RSUs will be subject to Michael\u2019s continuous service with Tivic through each applicable vesting date.<\/p>\n<p>\nThe foregoing RSU grant was unanimously approved by Tivic\u2019s board of directors and the compensation committee of the board, and such grants were inducements material to Michael entering into employment with Tivic, in accordance with Nasdaq Listing Rule 5635(c)(4). The foregoing equity grant was made outside of Tivic\u2019s Amended and Restated 2021 Equity Incentive Plan or any other equity incentive plan of the company.<\/p>\n<p><b>About Tivic Health<\/b><\/p>\n<p>\nTivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health. Tivic Health takes a multi-pronged approach to treating diseases caused by immune and autonomic nervous system dysregulation. The complement of bioelectronic and biologic medicines allows Tivic to target disorders and disease via both neural pathways and molecular approaches. Tivic Health\u2019s first FDA approved product ClearUP\u2122 is clinically proven to treat sinus pain and pressure, and is available through online retailers and commercial distributors. For more information about Tivic Health, visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.tivichealth.com&amp;esheet=54212442&amp;newsitemid=20250224860736&amp;lan=en-US&amp;anchor=https%3A%2F%2Fir.tivichealth.com&amp;index=1&amp;md5=3fa7a08a289ea1a592a5fa872bd78e6a\">https:\/\/ir.tivichealth.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p><i>This press release may contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate.<\/i><i>Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: statements regarding Tivic Health\u2019s development and advancement of Entolimod for the treatment of acute radiation syndrome (ARS) and any other indications that it may elect to license from Statera in the future; the future development of ncVNS treatment, Tivic Health\u2019s ability to commercialize products arising out of the license from Statera and Tivic Health\u2019s ncVNS treatment; the Tivic Health\u2019s plans to seek regulatory approval for such clinical products and Tivic Health\u2019s continued focus on developing Entolimod, including for the treatment of ARS and\/or any other indications it may elect to license in the future, and its ncVNS treatment, including in the epilepsy, post-traumatic stress disorder, and\/or ischemic stroke space; expected clinical utility, including which patient populations may be pursued; the timing and success of clinical studies and trials; market and other conditions; macroeconomic factors; and unexpected costs, charges or expenses that reduce Tivic Health\u2019s capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic Health\u2019s actual results to differ from those contained in the forward-looking statements, see Tivic Health\u2019s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading \u201cRisk Factors\u201d; as well as the company\u2019s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250224860736r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250224860736\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250224860736\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Hanover International, Inc.<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@tivichealth.com\">ir@tivichealth.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Neurology Biotechnology Pharmaceutical General Health Health Medical Devices Infectious Diseases Health Technology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250224860736\/en\/1936575\/3\/Tivic_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma FREMONT, Calif.&#8211;(BUSINESS WIRE)&#8211; Tivic Health\u00ae Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsibilities will include &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-816738","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma FREMONT, Calif.&#8211;(BUSINESS WIRE)&#8211; Tivic Health\u00ae Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsibilities will include &hellip; Continue reading &quot;Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-24T15:35:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250224860736r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team\",\"datePublished\":\"2025-02-24T15:35:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\\\/\"},\"wordCount\":1199,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250224860736r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\\\/\",\"name\":\"Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250224860736r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-02-24T15:35:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250224860736r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250224860736r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/","og_locale":"en_US","og_type":"article","og_title":"Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team - Market Newsdesk","og_description":"Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma FREMONT, Calif.&#8211;(BUSINESS WIRE)&#8211; Tivic Health\u00ae Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsibilities will include &hellip; Continue reading \"Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-24T15:35:59+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250224860736r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team","datePublished":"2025-02-24T15:35:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/"},"wordCount":1199,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250224860736r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/","name":"Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250224860736r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-02-24T15:35:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250224860736r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250224860736r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-executive-leadership-team\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=816738"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816738\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=816738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=816738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=816738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}